IBD in the elderly

Inflammatory Bowel Disease Monitor

Volumn 14, Issue 1, 2013, Pages 1-11

  Ruel, Joannie ^a   Ha, Christina ^b   Charpentier, Cloé ^c   Gower Rousseau, Corinne ^d   Colombel, Jean Frédéric ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITÉ DE ROUEN   (France)

^d UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTIBIOTIC AGENT; AZATHIOPRINE; BUDESONIDE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CIPROFLOXACIN; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; CYTOCHROME P450 INHIBITOR; EPHEDRINE; IMMUNOMODULATING AGENT; INFLIXIMAB; INFLUENZA VACCINE; KETOCONAZOLE; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; MMX; NONSTEROID ANTIINFLAMMATORY AGENT; PHENOBARBITAL; PHENYTOIN; RIFAMPICIN; SILDENAFIL; SIMVASTATIN; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; VARICELLA ZOSTER VACCINE; WARFARIN;

ABNORMAL LABORATORY RESULT; AGED; AGING; ANTIBIOTIC ASSOCIATED DIARRHEA; ANTIBIOTIC THERAPY; B CELL LYMPHOMA; BONE MARROW TOXICITY; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE INFECTION; COLORECTAL CANCER; COMORBIDITY; CONTROLLED DRUG RELEASE; CREATININE CLEARANCE; CROHN DISEASE; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG WITHDRAWAL; GERIATRIC PATIENT; HEADACHE; HOSPITALIZATION; HUMAN; HYPOMAGNESEMIA; IMMUNOMODULATION; INCIDENCE; INFECTION; INFLAMMATORY BOWEL DISEASE; KIDNEY DYSFUNCTION; METALLIC TASTE; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROPATHY; NON MELANOMA SKIN CANCER; NUTRITIONAL STATUS; ONSET AGE; OPPORTUNISTIC INFECTION; POLYPHARMACY; PRACTICE GUIDELINE; REVIEW; TREMOR; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; VACCINATION;

EID: 84896133652     PISSN: 14667401     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (105)

1. Cosnes J, Gower-Rousseau C, Seksik P et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011;140:1785-94.
2. Committee on the Future Health Care Workforce for Older Americans, Institute of Medicine. Retooling for an Aging America: Building the Health Care Workforce. The National Academies Press: Washington, DC, USA, 2008.
3. Charpentier C, Salleron J, Savoye G et al. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut 2013 Feb 13; Epub ahead of print.
4. Heresbach D, Alexandre JL, Bretagne JF et al. Crohn's disease in the over-60 age group: a population based study. Eur J Gastroenterol Hepatol 2004;16:657-64. (Pubitemid 38901633)
5. Loftus CG, Loftus EV Jr, Harmsen WS et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis 2007;13:254-61. (Pubitemid 46465905)
6. Piront P, Louis E, Latour P et al. Epidemiology of inflammatory bowel diseases in the elderly in the province of Liège. Gastroenterol Clin Biol 2002;26:157-61. (Pubitemid 34267135)
7. Kariyawasam VC, Lunney PC, Huang TD et al. Early treatment with immunomodulators is associated with change in the natural history of elderly onset inflammatory bowel disease - multicentre longitudinal study - Sydney, Australia 1942-2012. Gastroenterology 2013;144(5 Suppl. 1):S-10.
8. Travis S. Is IBD different in the elderly? Inflamm Bowel Dis 2008;14(Suppl. 2):S-12-3.
9. Bernstein CN, Wajda A, Svenson LW et al. The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am J Gastroenterol 2006;101:1559-68. (Pubitemid 43980630)
10. Wagtmans MJ, Verspaget HW, Lamers CB et al. Crohn's disease in the elderly: a comparison with younger adults. J Clin Gastroenterol 1998;27:129-33. (Pubitemid 28432262)
11. Harper PC, McAuliffe T, Beeken WL. Crohn's disease in the elderly. A statistical comparison with younger patients matched for sex and duration of disease. Arch Intern Med 1986;146:753-5. (Pubitemid 16037693)
12. Polito JM, Childs B, Mellits ED et al. Crohn's disease: influence of age at diagnosis on site and clinical type of disease. Gastroenterology 1996;111:580-6. (Pubitemid 26293220)
13. Juneja M, Baidoo L, Schwartz MB et al. Geriatric inflammatory bowel disease: phenotypic presentation, treatment patterns, nutritional status, outcomes, and comorbidity. Dig Dis Sci 2012;57:2408-15.
14. Lakatos PL, David G, Pandur T et al. IBD in the elderly population: results from a population-based study in Western Hungary, 1977-2008. J Crohns Colitis 2011;5:5-13.
15. Loftus EV, Silverstein MD, Sandborn WJ et al. Ulcerative colitis in Olmsted County Minnesota 1940-1993: incidence prevalence and survival. Gut 2000;46:336-43. (Pubitemid 30313384)
16. Riegler G, Tartaglione MT, Carratu R et al. Age-related clinical severity at diagnosis in 1705 patients with ulcerative colitis: a study by GISC (Italian Colon-Rectum Study Group). Dig Dis Sci 2000;45:462-5. (Pubitemid 30171918)
17. Zimmerman J, Gavish D, Rachmilewitz D. Early and late onset ulcerative colitis: distinct clinical features. J Clin Gastroenterol 1985;7:492-8. (Pubitemid 16175467)
18. Vernier-Massouille G, Balde M, Salleron J et al. Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology 2008;135:1106-13.
19. Langholz E, Munkholm P, Davidsen M et al. Changes in extent of ulcerative colitis: a study on the course and prognostic factors. Scand J Gastroenterol 1996;31:260-6.
20. Gower-Rousseau C, Dauchet L, Vernier-Massouille G et al. The natural history of pediatric ulcerative colitis: a population-based cohort study. Am J Gastroenterol 2009;104:2080-8.
21. Manten E, Green J, Bartholomew C. Primary care considerations in the management of inflammatory bowel disease patients. Practical Gastroenterol 2012;XXXVI(4);48-54.
22. Ha C, Katz S. Clinical outcomes and management of inflammatory bowel disease in the older patient. Curr Gastroenterol Rep 2013;15:310-8.
23. Parian AM, Ha C. Su1130 Severe polypharmacy and major medication interactions are associated with increasing age and comorbidity among inflammatory bowel disease patients. Gastroenterology 2013;144(5 Suppl. 1):S-406.
24. Loftus EV Jr, Guérin A, Yu AP et al. Increased risks of developing anxiety and depression in young patients with Crohn's disease. Am J Gastroenterol 2011;106:1670-7.
25. Link between depression, medical comorbidities underscores need for screening. Cardiology News Digital Network: Presented by Dr Margaret A Ege at the Annual Association of Geriatric Psychiatry's Annual Meeting 2012, Los Angeles, CA, USA. Available online at: http://www.ecardiologynews.com/index.php? id=8628&cHash=071010&tx-ttnews[tt-news]=142111. Accessed August 2013.
26. Feagan BG. Editorial: 5-ASA therapy for active Crohn's disease: old friends, old data and a new conclusion. Clin Gastroenterol Hepatol 2004;2:376-8. (Pubitemid 38561233)
27. Steinhart AH, Forbes A, Mills EC et al. Systematic review: the potential influence of mesalazine formulation on maintenance of remission in Crohn's disease. Aliment Pharmacol Ther 2007;25:1389-99. (Pubitemid 46848885)
28. Solberg IC, Vatn MH, Hoie O et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 2007;5:1430-8. (Pubitemid 350181602)
29. Muller AF, Stevens PE, McIntyre AS et al. Experience of 5-aminosalicylate nephrotoxicity in the United Kingdom. Aliment Pharmacol Ther 2005;21:1217-24. (Pubitemid 40733487)
30. Loftus EV Jr, Kane SV, Bjorkman D. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2004;19:179-89. (Pubitemid 38174887)
31. So K, Bewshea CM, Heap GA et al. 638 5-Aminosalicylate (5-ASA) induced nephrotoxicity in inflammatory bowel disease. Gastroenterology 2013;144(5 Suppl. 1):S-112.
32. van Staa TP, Travis S, Leufkens HG et al. 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. Gastroenterology 2004;126:1733-9. (Pubitemid 38736338)
33. Hung CK, Gitman M, Feldstein R et al. Long term effects of 5-aminosalicyclic acid use on renal function in the elderly with inflammatory bowel disease. Am J Gastroenterol 2012;107(Suppl. 1):S635(1573).
34. Dignass A, Lindsay JO, Sturm A et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012;6:991-1030.
35. Wells PS, Holbrook AM, Crowther NR et al. Interactions of warfarin with drugs and food. Ann Intern Med 1994;121:676-83.
36. de Boer NK, Wong DR, Jharap B et al. Dose dependent influence of 5-aminosalicylates on thiopurine metabolism. Am J Gastroenterol 2007;102:2747-53. (Pubitemid 350179331)
37. Cosnes J, Cattan S, Blain A et al. Long-term evolution of disease behaviour of Crohn's disease. Inflamm Bowel Dis 2002;8:244-50. (Pubitemid 34784976)
38. Faubion WA Jr, Loftus EV Jr, Harmsen WS et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001;121:255-60. (Pubitemid 32729372)
39. Akerkar GA, Peppercorn MA, Hamel MB. Corticosteroid-associated complications in elderly Crohn's disease patients. Am J Gastroenterol 1997;92:461-4. (Pubitemid 27108182)
40. Han PD, Burke A, Baldassano RN et al. Nutrition and inflammatory bowel disease. Gastroenterol Clin North Am 1999;28:423-43. (Pubitemid 29306486)
41. Dignass A, Van Assche G, Lindsay JO et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010;4:28-62.
42. Seow CH, Benchimol EI, Griffiths AM et al. Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2008;(3):CD000296.
43. Sandborn WJ, Travis S, Moro L et al. Once-daily budesonide MMX extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I Study. Gastroenterology 2012;143:1218-26.
44. Schoon EJ, Bollain S, Mills PR et al. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease. Clin Gastroenterol Hepatol 2005;3:113-21. (Pubitemid 40220306)
45. Frey BM, Frey FJ. Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet 1990;19:126-46. (Pubitemid 20211324)
46. Greenwald DA, Brandt LJ. Inflammatory bowel disease after age 60. Curr Treat Options Gastroenterol 2003;6:213-25.
47. Pineton de Chambrun GP, Torres J, Darfeuille-Michaud A et al. The role of anti(myco) bacterial interventions in the management of IBD: is there evidence at all? Dig Dis 2012;30:358-67.
48. Khan KJ, Ullman TA, Ford AC et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011;106:661-73.
49. Freeman CD, Klutman NE, Lamp KC. Metronidazole. A therapeutic review and update. Drugs 1997;54:679-708. (Pubitemid 27480240)
50. Shakeri-Nejad K, Stahlmann R. Drug interactions during therapy with three major groups of antimicrobial agents. Expert Opin Pharmacother 2006;7:639-51.
51. Beaugerie L, Brousse N, Bouvier AM et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009;374:1617-25.
52. Kandiel A, Fraser AG, Korelitz BI et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005;54:1121-5. (Pubitemid 41025906)
53. Siegel CA, Marden SM, Persing SM et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 2009;7:874-81.
54. Khan N, Koleva YN, Abbas A. 641 Is there any residual risk of lymphoma after stopping thiopurines? A nationwide retrospective cohort from the Veterans' Affairs Healthcare System. Gastroenterology 2013;144(5 Suppl. 1):S-112-3.
55. Peyrin-Biroulet L, Khosrotehrani K, Carrat F et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011;141:1621-8.
56. Ansari A, Patel N, Sanderson J et al. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2010;31:640-7.
57. Govani SM, Higgins PD. Combination of thiopurines and allopurinol: adverse events and clinical benefit in IBD. J Crohns Colitis 2010;4:444-9.
58. Feagan BG, Rochon J, Fedorak RN et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995;332:292-7.
59. Kamel OW, van de Rijn M, Hanasono MM et al. Immunosuppression-associated lymphoproliferative disorders in rheumatic patients. Leuk Lymphoma 1995;16:363-8.
60. Mariette X, Cazals-Hatem D, Warszawki J et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 2002;99:3909-15. (Pubitemid 35332027)
61. Magro F, Peyrin-Biroulet L, Sokol H et al. Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III). J Crohns Colitis 2013 May 27; Epub ahead of print.
62. Laharie D, Bourreille A, Branche J et al. Cyclosporin versus infliximab in severe acute ulcerative colitis refractory in intravenous steroids: a randomized trial. Gastroenterology 2011;140(5 Suppl. 1):S-112.
63. Katz S, Pardi DS. Inflammatory bowel disease of the elderly: frequently asked questions (FAQs). Am J Gastroenterol 2011;106:1889-97.
64. Toruner M, Loftus EV Jr, Harmsen WS et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008;134:929-36. (Pubitemid 351451967)
65. Cottone M, Kohn A, Daperno M et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol 2011;9:30-5.
66. Lichenstein GR, Feagan BG, Cohen RD et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4:621-30.
67. Bhushan A, Pardi DS, Loftus EV et al. 413 Age is not associated with adverse events from biologic therapy in patients with inflammatory bowel disease. Gastroenterology 2010;138(5 Suppl. 1):S-62.
68. Colombel JF, Loftus EV Jr, Tremaine WJ et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology 2004;126:19-31. (Pubitemid 38040720)
69. Ljung T, Karlen P, Schmidt D et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004;53:849-53. (Pubitemid 38662135)
70. Desai A, Zator ZA, de Silva P et al. Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013;19:309-15.
71. Lichtenstein GR, Cohen RD, Feagan BG et al. 490 Safety of infliximab and other Crohn's disease therapies - TREAT™ Registry Data with nearly 15,000 patient-years of follow-up. Gastroenterology 2006;130(4 Suppl. 2):A-71.
72. Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infection and mortality in patients with Crohn's Disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol 2012;107:1409-22.
73. Krok KL, Lichtenstein GR. Nutrition in Crohn's disease. Curr Opin Gastroenterol 2003;19:148-53.
74. Chandra RK. Effect of vitamin and trace-element supplementation on immune responses and infection in elderly subjects. Lancet 1992;340:1124-7.
75. Rahier JF, Ben-Horin S, Chowers Y et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009;3:47-91.
76. Gavazzi G, Krause KH. Ageing and infection. Lancet Infect Dis 2002;2:659-66. (Pubitemid 35265061)
77. Solana R, Pawelec G, Tarazona R. Aging and innate immunity. Immunity 2006;24:491-4. (Pubitemid 43728154)
78. Arvin AM. Varicella-zoster virus. Clin Microbiol Rev 1996;9:361-81. (Pubitemid 26245616)
79. Tremaine WJ, Timmons LJ, Loftus EV Jr et al. Age at onset of inflammatory bowel disease and the risk of surgery for non-neoplastic bowel disease. Aliment Pharmacol Ther 2007;25:1435-41. (Pubitemid 46848894)
80. Ha CY, Bayless TM, Bitton A et al. Sa1248 Late adult-onset inflammatory bowel disease patients require surgery earlier during their disease course compared to early adult-onset patients. Gastroenterology 2012;142(5 Suppl. 1):S-253-4.
81. Kaplan GG, Hubbard J, Panaccione R et al. Risk of comorbidities on postoperative outcomes in patients with inflammatory bowel disease. Arch Surg 2011;146:959-64.
82. Page MJ, Poritz LS, Kunselman SJ et al. Factors affecting surgical risk in elderly patients with inflammatory bowel disease. J Gastrointest Surg 2002;6:606-13. (Pubitemid 40433515)
83. Ha C, Bayless T, Wick E. 104 Increased incidence of post-operative complications in older inflammatory bowel disease patients having intestinal surgery. Gastroenterology 2012;142(5 Suppl. 1):S-25.
84. Almogy G, Sachar DB, Bodian CA et al. Surgery for ulcerative colitis in elderly persons: changes in indications for surgery and outcome over time. Arch Surg 2001;136:1396-400. (Pubitemid 33117047)
85. Kaplan GG, McCarthy EP, Ayanian JZ et al. Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology 2008;134:680-7.
86. Delaney CP, Remzi FH, Gramlich T et al. Equivalent function, quality of life and pouch survival rates after ileal pouch-anal anastomosis for indeterminate and ulcerative colitis. Ann Surg 2002;236:43-8. (Pubitemid 34686449)
87. Delaney CP, Fazio VW, Remzi FH et al. Prospective, age-related analysis of surgical results, functional outcome, and quality of life after ileal pouch-anal anastomosis. Ann Surg 2003;238:221-8. (Pubitemid 38174496)
88. Delaney CP, Dadvand B, Remzi FH et al. Functional outcome, quality of life, and complications after ileal pouch-anal anastomosis in selected septuagenarians. Dis Colon Rectum 2002;45:890-4. (Pubitemid 34761468)
89. Anathakrishnan AN, McGinley EL, Binion DG. Inflammatory bowel disease in the elderly is associated with worse outcomes: a national study of hospitalizations. Inflamm Bowel Dis 2009;15:182-9.
90. Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008;103:2272-80.
91. Ananthakrishnan AN, McGinley EL. Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases. J Crohns Colitis 2013;7:107-12.
92. Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 2008;57:205-10. (Pubitemid 351158048)
93. Gearhart SL, Nathan H, Pawlik TM et al. Outcomes from IBD-associated and non-IBD-associated colorectal cancer: a Surveillance Epidemiology and End Results Medicare study. Dis Colon Rectum 2012;55:270-7.
94. Ali RA, Dooley C, Comber H et al. Clinical features, treatment, and survival of patients with colorectal cancer with or without inflammatory bowel disease. Clin Gastroenterol Hepatol 2011;9:584-9.e1-2.
95. Ekbom A, Helmick C, Zack M et al. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990;323:1228-33. (Pubitemid 20366527)
96. Karlen P, Lofberg R, Brostrom O et al. Increased risk of cancer in ulcerative colitis: a population-based cohort study. Am J Gastroenterol 1999;94:1047-52. (Pubitemid 29173626)
97. Rutter M, Saunders B, Wilkinson K et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004;126:451-9. (Pubitemid 38182302)
98. Gupta RB, Harpaz N, Itzkowitz S et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007;133:1099-105; quiz 1340-1.
99. Torres J, Pineton de Chambrun G, Itzkowitz S et al. Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease. Aliment Pharmacol Ther 2011;34:497-508.
100. Karvellas CJ, Fedorak RN, Hanson J et al. Increased risk of colorectal cancer in ulcerative colitis patients diagnosed after 40 years of age. Can J Gastroenterol 2007;21:443-6. (Pubitemid 47307716)
101. Baars JE, Kuipers EJ, van Haastert M et al. Age at diagnosis of inflammatory bowel disease influences early development of colorectal cancer in inflammatory bowel disease patients: a nationwide, long-term survey. J Gastroenterol 2012;47:1308-22.
102. van Schaik F, Mooiweer E, van der Have M et al. Adenomas in patients with inflammatory bowel disease are associated with an increased risk of advanced neoplasia. Inflamm Bowel Dis 2013;19:342-9.
103. Khan N, Cole EB, Abbas A et al. Mo1240 Colorectal cancer recurrence following partial colectomy for colorectal cancer in patients with ulcerative colitis. Gastroenterology 2013;144(5 Suppl. 1):S-615.
104. Hanauer SB, Wagner CL, Bala M et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004;2:542-53. (Pubitemid 38834038)
105. Virgin HW, Todd JA. Metagenomics and personalized medicine. Cell 2011;147:44-56.